What is the typical ipamorelin dose?
Research-protocol ipamorelin doses typically span 100-300 mcg per dose on a once-daily or twice-daily subcutaneous schedule. The dose range derives from the original Novo Nordisk research program and subsequent investigator-driven studies. Combined-research protocols pairing ipamorelin with CJC-1295 No DAC typically use the same per-component dose range.
What the research literature says
Ipamorelin’s dose range was characterised across the original Novo Nordisk research program: the Raun first-selective-GHS characterisation (PMID 9849822) and the Johansen pharmacokinetic study with the ~2-hour half-life finding (PMID 9879640). The Venkova rodent postoperative-ileus work (PMID 19289567) and the Beck human proof-of-concept trial (PMID 25331030) extended the dose-response framework into investigator-driven studies.
The 100-300 mcg per dose tier reflects the dose-response curve characterised in these studies — GH-release pharmacology saturates at doses past this range, so higher doses don’t produce proportionately larger GH-release responses. The pulsatile pharmacology with the ~2-hour half-life supports either once-daily (pre-sleep fasted) or twice-daily (pre-sleep plus morning fasted) administration.
The combined CJC-1295 + Ipamorelin Blend format pairs ipamorelin with the GHRH-analogue arm at the canonical 5 mg + 5 mg per-vial loadings. Researchers using the blend typically maintain the same per-component dose tier (100-300 mcg per dose of each component delivered together).
Why this matters in research context
The 100-300 mcg per dose tier is the operational anchor for most ipamorelin research protocols. Higher doses produce diminishing returns due to receptor-saturation kinetics; lower doses may not produce reliably-measurable GH-release responses. The administration timing matters as much as the dose — pre-sleep fasted dosing maximises alignment with the natural GH-secretion peak.
Related compounds
- Ipamorelin 10mg — the compound covered by this answer
- CJC-1295 + Ipamorelin Blend — combined-formulation
Related research questions
- What is the half-life of ipamorelin?
- How much bacteriostatic water with ipamorelin?
- What time of day should CJC-1295 and ipamorelin be administered?
References
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552-561. [PMID 9849822]
- Johansen PB et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica 1998;28(11):1083-1095. [PMID 9879640]
- Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther 2009;329(3):1110-1116. [PMID 19289567]
- Beck DE et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014;29(12):1527-1534. [PMID 25331030]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Ipamorelin is sold strictly as a research-grade reagent for laboratory and bench research applications.